Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Income from Continuing Operations (2016 - 2023)

Endonovo Therapeutics has reported Income from Continuing Operations over the past 12 years, most recently at 766170.0 for Q3 2023.

  • Quarterly results put Income from Continuing Operations at 766170.0 for Q3 2023, down 26.98% from a year ago — trailing twelve months through Sep 2023 was 4404143.0 (down 39.98% YoY), and the annual figure for FY2022 was 18474835.0, down 495.02%.
  • Income from Continuing Operations for Q3 2023 was 766170.0 at Endonovo Therapeutics, down from 2063660.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ENDV hit a ceiling of 7230502.0 in Q1 2023 and a floor of 12932135.0 in Q4 2022.
  • Median Income from Continuing Operations over the past 5 years was 1523674.0 (2021), compared with a mean of 1619043.42.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 639.66% in 2022 and later surged 399.62% in 2023.
  • Endonovo Therapeutics' Income from Continuing Operations stood at 5664537.0 in 2019, then surged by 64.16% to 2030310.0 in 2020, then surged by 218.03% to 2396330.0 in 2021, then tumbled by 639.66% to 12932135.0 in 2022, then soared by 94.08% to 766170.0 in 2023.
  • The last three reported values for Income from Continuing Operations were 766170.0 (Q3 2023), 2063660.0 (Q2 2023), and 7230502.0 (Q1 2023) per Business Quant data.